Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFLUENCE trial of targeted versus standard fludarabine exposure before tisagenlecleucel
NL-OMON61050Phase 3Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fludarabine and tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Event-free survival. Started Jun 2026; status: recruiting.
02
Drugs
fludarabinetisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NL-OMON61050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61050.